Vitiligo

This study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…

This study tests a cream called ruxolitinib in 180 children with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. Participants will apply the cream daily for several mont…

This study tests an experimental drug called GIA632 in 210 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the drug can safely restore skin color and to find the best dose for future studies. Participants will receive e…

This study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …

This study tests whether a cream containing ruxolitinib (Opzelura) combined with corticosteroid injections or pills can improve facial vitiligo. It includes people aged 12 and older with active, non-segmental vitiligo affecting the face. Participants use the cream twice daily and…

This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential ben…

This trial tests whether applying tyrosine or 5-fluorouracil to the skin, combined with a fractional erbium YAG laser, can help restore color in people with focal vitiligo. Vitiligo is an autoimmune condition that causes white patches by destroying pigment-making cells. The study…

This Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers mea…

This study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…

This study tests a cream called ruxolitinib in children aged 6 to 12 with nonsegmental vitiligo, a condition that causes white patches on the skin. The cream is applied twice daily to affected areas. The goal is to see if it can safely restore skin color. About 250 children will …

This trial tests an experimental drug called QY201 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take QY201 or a placebo tablet twice daily for 24 weeks. The main goal is to see if QY201 can reduce the amount of facial skin…

This study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if t…

This study looks at whether taking coenzyme Q10 and vitamin C, alone or together, can improve healing and reduce dark gum color after surgical gum depigmentation. The trial involves 20 healthy adults with dark gums who undergo a simple scalpel procedure to remove pigmented tissue…

This study tests whether a new drug called EI-001 can help people with vitiligo, a condition that causes white patches on the skin. The drug works by calming the immune system to reduce inflammation. About 45 adults with nonsegmental vitiligo will receive either EI-001 or a place…

This study tests whether taking a daily pill (ritlecitinib) plus twice-weekly narrowband UVB light therapy works better than the pill alone for vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much skin…

This early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…

This Phase 2 study tests whether adding Melanotan II (a synthetic hormone-like drug) to standard narrowband UV-B light therapy helps restore skin color in adults with stable nonsegmental vitiligo. About 60 participants will receive either the drug or a placebo, plus light therapy…

This study tests a new drug called SHR0302, given as a tablet and a gel, for people with non-segmental vitiligo. The goal is to see if it can safely and effectively bring back skin color. About 176 adults aged 18 to 75 will take part, and some will receive a placebo to compare re…

This early-stage trial compares two treatments for limited vitiligo: microneedling with 5-fluorouracil (5FU) every two weeks versus a strong steroid cream applied twice daily. Forty participants aged 5 to 70 with vitiligo on 10% or less of their body will be treated for 12 weeks.…

This early-stage trial tests whether CGB-600 gel can safely reduce white patches from vitiligo on the face and neck. Thirty-six adults will apply the gel or a placebo twice daily for 24 weeks. Researchers will check for side effects and measure if the patches shrink by at least 5…

This study tests a new effervescent (fizzing) powder containing 5-fluorouracil to treat vitiligo, a condition that causes white patches on the skin. Sixty people with stable vitiligo will apply either the new fizzing powder or plain 5-fluorouracil powder to their patches. The goa…

This study is testing a cream called ruxolitinib on 170 people with vitiligo, a skin condition that causes white patches. The goal is to find out what factors help the cream work best. Participants must be 12 or older and have mild to moderate vitiligo. They will stop other treat…

This study tests a new drug called VC005 in 120 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants will take either VC005 or a placebo daily for 52 weeks. The main goal is to see if the drug can reduce the size of white patches on …

This study tests if using ultrasound (phonophoresis) to push betamethasone cream deeper into the skin can help control vitiligo, a condition that causes white patches. Researchers will enroll 60 adults with vitiligo who are otherwise healthy. The goal is to see if this approach r…

This early-stage trial tests a new drug called FB102 in 64 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Half will get the drug and half a placebo, both given by IV. The main goal is to check safety and see if the drug helps bring back ski…

This study tests a procedure where a person's own skin cells are transplanted onto stable white patches caused by vitiligo. The goal is to see how well and how safely it restores color over the long term. The trial will enroll 30 people with stable vitiligo who have not responded…

This study tests two ways of puncturing white patches of skin—using a single needle or a microneedling device—followed by UV light therapy to see which helps restore pigment better. Eighty adults with stable non-segmental vitiligo will receive six sessions over 24 weeks. The goal…

This study tests if injecting vitamin C and glutathione into dark gums can lighten them as well as surgery. About 30 adults with gum pigmentation will be randomly assigned to either injection or scalpel removal. The main goal is to see how much the color improves, and the study a…

This study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …

This study follows 1,000 people with chronic inflammatory skin diseases, such as eczema, psoriasis, and rosacea, over time. Researchers will collect detailed clinical data and biological samples to see which factors correlate with disease activity and progression. The goal is to …

This observational registry will follow 2,500 adults and adolescents with nonsegmental vitiligo to understand how the disease presents and progresses over time. Participants continue their usual care with a dermatologist. No experimental treatment is given; the goal is to collect…

This study looks at the bacteria living on the skin and in the gut of 100 adults with and without vitiligo. Researchers want to see if people with active or stable vitiligo have different bacteria compared to healthy volunteers. No treatments or drugs are given—just samples colle…

This study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…